AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00980057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Echo
Description: Standard BiV pacing with settings optimized using a standardized echocardiographic protocol
Study NCT00003594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Study NCT00003594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00003594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT00003594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/meal feed
Description: Weight-maintaining diet relatively high in sugar fed as two large meals daily
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/nibble
Description: Weight-maintaining diet relatively high in sugar fed as 8 meals daily
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin+Standard Maintenance Therapy
Description: Addition of IV Inotuzumab ozogamicin before Maintenance Therapy
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: p.o. Imatinib
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/meal feed
Description: Weight-maintaining diet relatively high in fat fed as two large meals daily
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/nibble
Description: Weight-maintaining diet relatively high in fat fed as 8 small meals daily
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar/ 3 meals a day
Description: Weight-maintaining diet relatively high in sugar fed as 3 meals daily
Study NCT02075710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat/ 3 meals a day
Description: Weight-maintaining diet relatively high in fat fed as 3 meals daily
Study NCT00506662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target, s.c. (under the skin) injection, once daily
Study NCT00506662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Treat-to-target, s.c. (under the skin) injection, once daily
Study NCT01308554 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: sterile normal saline
Description: Bilateral TAP block using 20 ml of normal sterile saline per block.
Study NCT01308554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine
Description: Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
Study NCT01925677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: da Vinci® Single-Site™
Description: Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
Study NCT02161731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib
Description: Oral administration
Study NCT02161731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Oral administration
Study NCT02161731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Oral administration
Study NCT01408485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy™ Cool Flex™ Irrigated Ablation System
Description: The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:~* Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter~* IBI 1500T9 V1.43 RF Generator
Study NCT03772691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral suspension
Description: • The vesico-vaginal space was found between the bladder and the anterior vaginal wall in the fascia plane. A polypropylene mesh (25 , 25 cm, Ethicon, Inc., Somerville, NJ) was cut to obtain two long arms (15-20 mm wide) and a rectangular piece (4-7 cm wide).
Study NCT03772691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacropexy
Description: • The mesh is fixed on the anterior longitudinal ligament of sacrum with separated number 1 prolene sutures. The other end of the mesh is passed through the peritoneal tunnel and fixed to the cervix using prolene 1 and vicryl o sutures.
Study NCT02771002 — intervention group
Intervention type: DEVICE
Intervention: Peripheral Perfusion index by Carescape Patientenmonitor
Description: Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
Study NCT02949869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Sonography
Description: As described previously
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-tioguanine+Standard Maintenance Therapy
Description: Addition of p.o. 6-tioguanine to Standard Maintenance Therapy
Study NCT04030611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: tongue diagnosis system
Description: This study apply TCM diagnostic tools for clinical diseases, providing objective diagnostic data for evaluation to assess the association of blood stasis and DR.
Study NCT04307576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: IV Blinatumomab
Study NCT01539135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Study NCT01539135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: 20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
Study NCT01716689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral cyclophosphamide
Description: 50mg daily
Study NCT01087489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Description: The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
Study NCT01087489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3.5% ophthalmic lidocaine gel
Description: The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
Study NCT02150135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncothermia
Description: Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
Study NCT02699684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses with EOBO-41
Description: Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
Study NCT02699684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lenses
Description: Lotrafilcon B contact lenses packaged with copolymer 845
Study NCT02699684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hydrogen peroxide-based lens care solution
Description: Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
Study NCT02699684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lenses
Description: Commercially-available saline solution used as needed
Study NCT02699684 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Saline solution for rinsing contact lens case
Description: Commercially-available solution used as needed
Study NCT02142855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concentric Exercise Training
Description: 8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
Study NCT02142855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise Training
Description: 8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
Study NCT00810043 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphon® Curette
Description: The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment A (current tablet formulation)
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment B (new tablet formulation)
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment C (new capsule formulation)
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment D (current tablet formulation)
Study NCT01113944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1
Study NCT01113944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Study NCT02925507 — intervention group
Intervention type: OTHER
Intervention: Swallowing Screen
Description: Patient will be ask to undergo a swallowing screen by study staff
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BILR 355 - Treatment E (new capsule formulation)
Study NCT02253940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT01368952 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pure prone positioning
Description: Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03233711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04123444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: Continuously infusion for 72 hours. treatment dose 1 ng/kg/min
Study NCT04123444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: Continuously infusion for 72 hours.
Study NCT01507571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Description: Dignity Therapy is a brief psychotherapeutic intervention consisting of:~1. a tape-recorded session with the patient using the DT question protocol~2. Transcription of the interview, which is then edited~3. A session where the edited transcript is returned to the patient who can give it to family members or friends.~If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by.
Study NCT01722357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
Study NCT01722357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
Study NCT00305734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00305734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00305734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03528590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: size 3 i-gel supraglottic airway device
Description: Use size 3 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
Study NCT03528590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: size 4 i-gel supraglottic airway device
Description: Use size 4 i-gel® in anesthetized, paralyzed female patients weighing 50 to 60 kilograms who undergo breast surgery.
Study NCT06280053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HealiAid Collagen Wound Dressing
Description: HealiAid is an absorbable collagen wound dressing. It is fabricated by fibrous collagen matrix, in which the collagen is purified from bovine Achilles tendons. HealiAid can be applied easily by covering directly to the clean wound sites.
Study NCT03700346 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: microdialysis
Description: Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained by using muscle microdialysis
Study NCT04244721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preschool Autism Communication Therapy (PACT)
Description: Professionals guide parents in the PACT therapy by videoconference. Sessions between parent and professionals are every 15 days for 6 months. Each session lasts one hour. At the end of the 12 sessions, additional booster sessions (one session per month over 6 months) will allow parents to maintain their skills. Parents will use therapy with their children in daily home practice. The aims of PACT therapy is to improve synchrony in the communication between the child and the parents. Improvement of the synchrony will mediate the decrease of autism symptoms of the child.
Study NCT04244721 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Children will receive therapies available in the community as speech language therapist or occupational therapist.
Study NCT03912155 — intervention group
Intervention type: OTHER
Intervention: Multi-scale analysis of physiological brain networks
Description: It will be simultaneously record the surface EEG, the MEG and in patients only the intracerebral EEG (SEEG). In the case of SEEG with micro contacts, these additional signals will also be recorded in parallel and will provide greater sensitivity to high frequency activities. The physiological networks will be studied in patients thanks to stimulations (external or intracerebral) carried out within the framework of the functional cartography, and the pathological networks thanks to measures in state of rest. For external stimulation protocols, it will be constitute a reference base in MEG and EEG alone (non-invasive) on control subjects.
Study NCT02066805 — intervention group
Intervention type: DRUG
Intervention: Database assessment of off-label XGEVA use
Description: No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
Study NCT01176890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: 1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied
Study NCT01038440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Safflower Oil
Description: One softgel consumed daily with food
Study NCT01038440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA
Description: Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
Study NCT01310621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bovine surfactant
Description: * Dose of diluted surfactant : 20ml/kg~* Type :Bovine surfactant~* Phospholipid concentration: 5 mg/ml~* Number of lavages to be given: 2 (10ml/kg each)
Study NCT04067544 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acupuncture
Description: The manualized acupuncture treatment (AT) intervention will be designed by Dr. Budhathoki and Dr. Taylor-Swanson and administered by Dr. Budhathoki and members of Huntsman acupuncture team. Ten sessions of AT will be delivered: twice per week for 2 weeks, thereafter once per week for six weeks, with a total of 9 treatments during a two-month course. Each session will last 45-60 minutes, with acupuncture needles retained 30-40 minutes. A minimum of 8 treatments must be received by each participant with no more than 9 days' gap between treatments permitted. Concurrent medications are allowed as prescribed and will be tracked in the study and analyzed as potential confounders.~Participants in the study will undergo study interview and fMRI at the following two time points: within 9 days after baseline following enrollment and within one week of acupuncture treatment completion.
Study NCT01176890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.~After four hours an ad libitum meal will be supplied
Study NCT02623699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Administered as specified in the treatment arm.
Study NCT02623699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT00439894 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: blood draw at baseline, week 12 and week 24
Study NCT02371018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nepro
Description: Patients will be asked to consume a single 8 oz can of Nepro
Study NCT01279980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
Study NCT01279980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic wound catheter
Description: The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
Study NCT00971542 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen \& adjuvant, or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups.
Study NCT01954810 — intervention group
Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: Japanese encephalitis chimeric vaccine (JECV)
Description: Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
Study NCT03233711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patient Observation
Description: Undergo observation
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proctoscopy
Description: Undergo proctoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Proctoscopy
Description: Undergo proctoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sigmoidoscopy
Description: Undergo sigmoidoscopy
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study NCT03233711 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: X-Ray Imaging
Description: Undergo chest x-ray
Study NCT03046251 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab
Study NCT03374436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Carbohydrate Sedentary
Description: Three high-carbohydrate meals will be consumed (breakfast, lunch, and dinner) at \~3 hour intervals while participants remain in a seated position for the entire 9 hour intervention period.
Study NCT03184233 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rapid ventricular pacing
Description: Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture